Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
随着制药巨头争相加入肥胖治疗市场，罗氏、辉瑞竞相寻找下一个奥泽米克
How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years — getting a Covid vaccine to market during the pandemic, and now tackling the obesity epidemic.
在您的产品组合中拥有最新的大片是多么重要。近年来，制药行业一遍又一遍地展示了这一点——在疫情期间将Covid疫苗推向市场，现在正在应对肥胖症的流行。
Those with obesity drugs already on the market have proved, through their share price moves in the past months, what it means to have this type of treatment on your roster.
那些已经在市场上出售肥胖药物的人通过过去几个月的股价变动证明了将这种治疗列入名单意味着什么。
Novo Nordisk (NYSE:NVO) — with two obesity drugs Ozempic and Wegovy — has jumped by around 300% since it bought Ozempic to the market in 2019, while Eli Lilly (NYSE:LLY) is...
拥有两种肥胖药物Ozempic和Wegovy的诺和诺德（纽...
登录免费看全文
登录/注册
资讯热榜
更新时间